TITLE

Design, expression and characterization of a novel coexpression system of two antiarthritic molecules

AUTHOR(S)
Zhang, Wei; Wang, Fang; Yan, Jinqi; Zhang, Xiaojun; Wang, Yu; Jiang, Yunbo; Wang, Lin; Xu, Yuanji; Yu, Jiyun
PUB. DATE
July 2013
SOURCE
Applied Microbiology & Biotechnology;Jul2013, Vol. 97 Issue 14, p6301
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The complexity of rheumatoid arthritis (RA) pathogenesis makes combined blockade of multiple targets an attractive therapeutic strategy. The combination therapy with anti-TNF plus anti-T-cell has been mostly reported to provide greater efficacy than anti-TNF alone. TNFR (p75)-Fc fusion protein, which has been proven effective in clinics, is chosen as the TNF antagonist in this study. CTLA4-FasL fusion molecule, which has been well characterized in our previous studies for its suppressive effect in rat arthritis model, is chosen as the T-cell antagonist. In this study, furin cleavage site and 2A self-processing sequence were introduced to link upstream TNFR-Fc and downstream CTLA4-FasL and mediate separate coexpression of the two fusion proteins in a single recombinant adeno-associated virus (rAAV) vector. Using this expression system, we generated two fusion proteins with same size as their individual counterparts in vitro and in vivo, and the proteins desirably retained their parent biological activities. In vivo results demonstrated that furin-2A technology is able to regulate separate coexpression of these proteins under arthritic inflammatory conditions. This study describes a single rAAV vector for production of two antiarthritic molecules antagonizing both TNF and T cells, which may serve as an attractive expression system for RA gene therapy.
ACCESSION #
88785256

 

Related Articles

  • Optimising expression of the recombinant fusion protein biopesticide ω-hexatoxin-Hv1a/GNA in Pichia pastoris: sequence modifications and a simple method for the generation of multi-copy strains. Pyati, Prashant; Fitches, Elaine; Gatehouse, John // Journal of Industrial Microbiology & Biotechnology;Aug2014, Vol. 41 Issue 8, p1237 

    Production of recombinant protein bio-insecticides on a commercial scale can only be cost effective if host strains with very high expression levels are available. A recombinant fusion protein containing an arthropod toxin, ω-hexatoxin-Hv1a, (from funnel web spider Hadronyche versuta) linked...

  • FUSION EXPRESSION OF RECOMBINANT HUMAN BETA-DEFENSIN-3 AND ANALYSIS OF ITS BIOLOGICAL ACTIVITY. Gerashchenko, O.; Kovalchuk, V.; Boidunik, O.; Soldatkina, M.; Pogrebnoy, P. // Bulletin of Taras Shevchenko National University of Kyiv / Vestn;2014, Vol. 68 Issue 3, p98 

    Human beta-defensins (hBDs) are small cationic antimicrobial peptides with multiple biologic activities. The aim of the study was cloning, expression in E.coli, purification and in vitro analysis of biological activity of recombinant human beta-defensin-3 (rec-hBD-3). hBD-3 cDNA was cloned into...

  • Recombinant ESAT-6-CFP10 Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. Jackson-Sillah, Dolly; Cliff, Jacqueline M.; Mensah, Gloria Ivy; Dickson, Emmanuel; Sowah, Sandra; Tetteh, John K A.; Addo, Kwasi K.; Ottenhoff, Tom H. M.; Bothamley, Graham; Dockrell, Hazel M. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: Early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) are Mycobacterium tuberculosis (Mtb)–specific antigens that are secreted by actively metabolising bacteria and contribute to the virulence of the bacteria. Their ability to induce Treg and Th2...

  • Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Neumann, V.C.; Grindulis, K.A.; Hubball, S.; McConkey, B.; Wright, V. // British Medical Journal (Clinical Research Edition);10/15/1983, Vol. 287 Issue 6399, p1099 

    Compares the efficacy of penicillamine and sulphasalazine in treating rheumatoid arthritis. Capabilities of Sulphasalazine in producing remissions; Precautions on the intake of the drugs; Concerns on the side effects of penicillamine.

  • Auranofin or D-Penicillamine in the Treatment of Rheumatoid Arthritis. Hochberg, Marc C. // Annals of Internal Medicine;Oct86, Vol. 105 Issue 4, p528 

    Presents a study which compared the effectiveness of auranofin and d-penicillamine in the treatment of rheumatoid arthritis. Patients and methods; Results; Discussion.

  • Celecoxib has a better cardiorenal profile than diclofenac/ibuprofen.  // Reactions Weekly;11/11/2006, Issue 1127, p1 

    The article discusses research being done on the cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. It references a study by A. Whelton et al published in the October 2006 issue of "Kidney International" journal. The study found...

  • BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. Song, Shan-shan; Huang, Bei; Wang, Qing-tong; Wu, Yu-jing; Fu, Jing-jing; Zhang, Yun-fang; Chang, Yan; Chen, Jing-yu; Wu, Hua-xun; Wang, Di; Zhang, Ling-ling; Wei, Wei // Acta Pharmacologica Sinica;Mar2013, Vol. 34 Issue 3, p414 

    Aim:To investigate the therapeutic effects of BF02 on adjuvant arthritis (AA) in rats and the regulatory effects of BF02 on T lymphocyte function.Methods:SD rats received a single intradermal injection of Freund's complete adjuvant emulsion into the right hind metatarsal footpad. After the onset...

  • Cytokine blocker licensed for relief of rheumatoid arthritis symptoms.  // American Journal of Health-System Pharmacy;2/1/2002, Vol. 59 Issue 3, p225 

    Reports on the U.S. Food and Drug Administration's approval for Amgen Inc.'s marketing of anakinra, a recombinant protein that interferes with the binding of the cytokine interleukin-1 (IL-1) to the IL-1 type-1 receptor. Indication of IL-1 blocker for the reduction in signs and symptoms of...

  • Genetically Engineered Treatment for RA. Schwartz, Ronald M. // Nursing Homes: Long Term Care Management;Jan99, Vol. 48 Issue 1, p9 

    Provides information on a genetically engineered protein, etanercept, used in the treatment of patients with rheumatoid arthritis. Combination drugs recommended for treatment; Mechanism of action; Effectiveness of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics